Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Centessa Pharmaceuticals ( (CNTA) ) has provided an update.
On December 11, 2025, Centessa Pharmaceuticals announced the appointment of Dr. Mario Alberto Accardi as the new Chief Executive Officer, effective January 1, 2026. Dr. Accardi, who has been instrumental in leading Centessa’s Orexin Program, will succeed Dr. Saurabh Saha, who will transition to an advisory role. This leadership change marks a strategic shift for Centessa, as it intensifies its focus on advancing its orexin portfolio, particularly OX2R agonists, which are poised to address a range of neurological disorders. The company aims to capitalize on the promising growth opportunities in neuroscience, with key milestones expected in 2026, positioning itself at the forefront of this emerging therapeutic class.
The most recent analyst rating on (CNTA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Centessa Pharmaceuticals stock, see the CNTA Stock Forecast page.
Spark’s Take on CNTA Stock
According to Spark, TipRanks’ AI Analyst, CNTA is a Underperform.
Centessa Pharmaceuticals has a low overall stock score due to significant financial challenges, including ongoing losses, negative cash flow, and a bearish technical outlook. The lack of profitability reflected in the negative P/E ratio further contributes to the low score. Investors should be cautious, considering the company’s need for additional funding to sustain operations in the capital-intensive biotechnology industry.
To see Spark’s full report on CNTA stock, click here.
More about Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company focused on discovering, developing, and delivering transformational medicines. The company is pioneering therapies within its Orexin Receptor 2 (OX2R) agonist program, targeting excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue across neurological, neurodegenerative, and neuropsychiatric disorders.
Average Trading Volume: 1,472,953
Technical Sentiment Signal: Buy
Current Market Cap: $3.84B
For an in-depth examination of CNTA stock, go to TipRanks’ Overview page.